Published in J Infect Dis on October 01, 2011
Immunostimulatory Defective Viral Genomes from Respiratory Syncytial Virus Promote a Strong Innate Antiviral Response during Infection in Mice and Humans. PLoS Pathog (2015) 0.89
Nanoparticle vaccines encompassing the respiratory syncytial virus (RSV) G protein CX3C chemokine motif induce robust immunity protecting from challenge and disease. PLoS One (2013) 0.87
Maternal antibodies by passive immunization with formalin inactivated respiratory syncytial virus confer protection without vaccine-enhanced disease. Antiviral Res (2014) 0.87
Co-immunization with virus-like particle and DNA vaccines induces protection against respiratory syncytial virus infection and bronchiolitis. Antiviral Res (2014) 0.87
CX3CR1 Is Expressed in Differentiated Human Ciliated Airway Cells and Co-Localizes with Respiratory Syncytial Virus on Cilia in a G Protein-Dependent Manner. PLoS One (2015) 0.86
Incorporation of membrane-anchored flagellin or Escherichia coli heat-labile enterotoxin B subunit enhances the immunogenicity of rabies virus-like particles in mice and dogs. Front Microbiol (2015) 0.86
Baculovirus-expressed virus-like particle vaccine in combination with DNA encoding the fusion protein confers protection against respiratory syncytial virus. Vaccine (2014) 0.84
Subviral particle as vaccine and vaccine platform. Curr Opin Virol (2014) 0.83
Prokaryote-expressed M2e protein improves H9N2 influenza vaccine efficacy and protection against lethal influenza A virus in mice. Virol J (2013) 0.83
Additive protection induced by mixed virus-like particles presenting respiratory syncytial virus fusion or attachment glycoproteins. Antiviral Res (2014) 0.82
Respiratory syncytial virus-like nanoparticle vaccination induces long-term protection without pulmonary disease by modulating cytokines and T-cells partially through alveolar macrophages. Int J Nanomedicine (2015) 0.81
Virus-like nanoparticle and DNA vaccination confers protection against respiratory syncytial virus by modulating innate and adaptive immune cells. Nanomedicine (2014) 0.81
Newcastle disease virus-like particles: preparation, purification, quantification, and incorporation of foreign glycoproteins. Curr Protoc Microbiol (2013) 0.80
New Approaches for Immunization and Therapy against Human Metapneumovirus. Clin Vaccine Immunol (2015) 0.79
Antiviral activity of ginseng extract against respiratory syncytial virus infection. Int J Mol Med (2014) 0.79
Ginseng protects against respiratory syncytial virus by modulating multiple immune cells and inhibiting viral replication. Nutrients (2015) 0.79
Ginseng diminishes lung disease in mice immunized with formalin-inactivated respiratory syncytial virus after challenge by modulating host immune responses. J Interferon Cytokine Res (2014) 0.78
Parainfluenza virus 5 (PIV5) expressing wild-type or pre-fusion respiratory syncytial virus (RSV) fusion protein protect mice and cotton rats from RSV challenge. J Virol (2017) 0.77
Recombinant influenza virus carrying the conserved domain of respiratory syncytial virus (RSV) G protein confers protection against RSV without inflammatory disease. Virology (2014) 0.77
Induction of protective effector immunity to prevent pathogenesis caused by the respiratory syncytial virus. Implications on therapy and vaccine design. Immunology (2014) 0.77
Virus-like particle vaccine confers protection against a lethal newcastle disease virus challenge in chickens and allows a strategy of differentiating infected from vaccinated animals. Clin Vaccine Immunol (2014) 0.77
Virus-Like Nanoparticle Vaccine Confers Protection against Toxoplasma gondii. PLoS One (2016) 0.77
Innate and adaptive cellular phenotypes contributing to pulmonary disease in mice after respiratory syncytial virus immunization and infection. Virology (2015) 0.76
Protection conferred by virus-like particle vaccines against respiratory syncytial virus infection in mice by intranasal vaccination. Hum Vaccin Immunother (2015) 0.76
Chimeric rabies virus-like particles containing membrane-anchored GM-CSF enhances the immune response against rabies virus. Viruses (2015) 0.76
Mammalian Cell-Derived Respiratory Syncytial Virus-Like Particles Protect the Lower as well as the Upper Respiratory Tract. PLoS One (2015) 0.76
Alum Adjuvant Enhances Protection against Respiratory Syncytial Virus but Exacerbates Pulmonary Inflammation by Modulating Multiple Innate and Adaptive Immune Cells. PLoS One (2015) 0.75
Synthetic Biodegradable Microparticle and Nanoparticle Vaccines against the Respiratory Syncytial Virus. Vaccines (Basel) (2016) 0.75
Protection induced by virus-like particles containing Toxoplasma gondii microneme protein 8 against highly virulent RH strain of Toxoplasma gondii infection. PLoS One (2017) 0.75
Influenza M1 Virus-Like Particles Consisting of Toxoplasma gondii Rhoptry Protein 4. Korean J Parasitol (2017) 0.75
A Respiratory Syncytial Virus Vaccine Vectored by a Stable Chimeric and Replication-Deficient Sendai Virus Protects Mice without Inducing Enhanced Disease. J Virol (2017) 0.75
An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am J Epidemiol (1969) 6.85
Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease. Nat Med (2008) 3.17
Circulation patterns of genetically distinct group A and B strains of human respiratory syncytial virus in a community. J Gen Virol (1998) 3.06
Virus-like particle vaccine induces protective immunity against homologous and heterologous strains of influenza virus. J Virol (2007) 2.71
Circulation patterns of group A and B human respiratory syncytial virus genotypes in 5 communities in North America. J Infect Dis (2000) 2.13
Respiratory syncytial virus genetic and antigenic diversity. Clin Microbiol Rev (2000) 2.07
Defined recombinants of poliovirus and coxsackievirus: sequence-specific deletions and functional substitutions in the 5'-noncoding regions of viral RNAs. Virology (1988) 1.84
A chimeric A2 strain of respiratory syncytial virus (RSV) with the fusion protein of RSV strain line 19 exhibits enhanced viral load, mucus, and airway dysfunction. J Virol (2009) 1.63
Influenza vaccines based on virus-like particles. Virus Res (2009) 1.48
Newcastle disease virus-like particles containing respiratory syncytial virus G protein induced protection in BALB/c mice, with no evidence of immunopathology. J Virol (2009) 1.28
Virus-like particle vaccine protects against 2009 H1N1 pandemic influenza virus in mice. PLoS One (2010) 1.28
Venezuelan equine encephalitis virus replicon particles encoding respiratory syncytial virus surface glycoproteins induce protective mucosal responses in mice and cotton rats. J Virol (2007) 1.24
A bivalent influenza VLP vaccine confers complete inhibition of virus replication in lungs. Vaccine (2008) 1.24
Pulmonary immunity and immunopathology: lessons from respiratory syncytial virus. Expert Rev Vaccines (2008) 1.23
Live subgroup B respiratory syncytial virus vaccines that are attenuated, genetically stable, and immunogenic in rodents and nonhuman primates. J Infect Dis (1996) 1.21
Recombinant Sendai virus expressing the G glycoprotein of respiratory syncytial virus (RSV) elicits immune protection against RSV. J Virol (2004) 1.21
Kinetics of immune responses to influenza virus-like particles and dose-dependence of protection with a single vaccination. J Virol (2009) 1.20
Soluble respiratory syncytial virus fusion protein in the fully cleaved, pretriggered state is triggered by exposure to low-molarity buffer. J Virol (2011) 1.19
Single intranasal immunization with recombinant adenovirus-based vaccine induces protective immunity against respiratory syncytial virus infection. J Virol (2007) 1.08
Group-specific serum antibody responses in children with primary and recurrent respiratory syncytial virus infections. J Infect Dis (1991) 1.06
Humoral, mucosal, and cellular immune response to topical immunization with a subunit respiratory syncytial virus vaccine. J Infect Dis (1994) 0.99
Immunogenicity and efficacy of recombinant RSV-F vaccine in a mouse model. Vaccine (2007) 0.92
The immunogenicity, protective efficacy and safety of BBG2Na, a subunit respiratory syncytial virus (RSV) vaccine candidate, against RSV-B. Vaccine (2003) 0.92
CpG containing oligodeoxynucleotides are potent adjuvants for parenteral vaccination with the fusion (F) protein of respiratory syncytial virus (RSV). Vaccine (2001) 0.92
Absence of lung immunopathology following respiratory syncytial virus (RSV) challenge in mice immunized with a recombinant RSV G protein fragment. Virology (1999) 0.90
Developments and improvements in the manufacturing of human therapeutics with mammalian cell cultures. Trends Biotechnol (2000) 0.89
Identification of and human serum reactogenicity to neutralizing epitopes within the central unglycosylated region of the respiratory syncytial virus attachment protein. Clin Vaccine Immunol (2010) 0.88
Potential mechanisms causing delayed effects of respiratory syncytial virus infection. Am J Respir Crit Care Med (2001) 0.87
Cytotoxic T cell activity against the 22-kDa protein of human respiratory syncytial virus (RSV) is associated with a significant reduction in pulmonary RSV replication. Virology (1991) 0.85
Murine host responses to respiratory syncytial virus (RSV) following intranasal administration of a Protollin-adjuvanted, epitope-enhanced recombinant G protein vaccine. J Clin Virol (2009) 0.84
A single amino acid substitution in a recombinant G protein vaccine drastically curtails protective immunity against respiratory syncytial virus (RSV). Vaccine (2003) 0.80
Fixing a failed vaccine. Nat Med (2009) 0.80
QS-21 synergizes with recombinant interleukin-12 to create a potent adjuvant formulation for the fusion protein of respiratory syncytial virus. Viral Immunol (2000) 0.78
CD4+CD25+ T cells regulate virus-specific primary and memory CD8+ T cell responses. J Exp Med (2003) 4.56
Critical role for the chemokine receptor CXCR6 in NK cell-mediated antigen-specific memory of haptens and viruses. Nat Immunol (2010) 4.34
Gain-of-function experiments on H7N9. Science (2013) 3.67
Dissolving polymer microneedle patches for influenza vaccination. Nat Med (2010) 3.24
Virus-like particle vaccine induces protective immunity against homologous and heterologous strains of influenza virus. J Virol (2007) 2.71
Toward primary prevention of asthma. Reviewing the evidence for early-life respiratory viral infections as modifiable risk factors to prevent childhood asthma. Am J Respir Crit Care Med (2015) 2.33
Avian flu: Gain-of-function experiments on H7N9. Nature (2013) 2.32
Pause on avian flu transmission research. Science (2012) 2.24
Antigenic subversion: a novel mechanism of host immune evasion by Ebola virus. PLoS Pathog (2012) 2.09
Induction of heterosubtypic immunity to influenza virus by intranasal immunization. J Virol (2007) 2.06
Induction of long-term protective immune responses by influenza H5N1 virus-like particles. PLoS One (2009) 1.95
Immunoelectron microscopic evidence for Tetherin/BST2 as the physical bridge between HIV-1 virions and the plasma membrane. PLoS Pathog (2010) 1.85
Immunization by vaccine-coated microneedle arrays protects against lethal influenza virus challenge. Proc Natl Acad Sci U S A (2009) 1.82
HIP14, a novel ankyrin domain-containing protein, links huntingtin to intracellular trafficking and endocytosis. Hum Mol Genet (2002) 1.79
Transdermal influenza immunization with vaccine-coated microneedle arrays. PLoS One (2009) 1.78
Formulation and coating of microneedles with inactivated influenza virus to improve vaccine stability and immunogenicity. J Control Release (2009) 1.62
Differential pathogenesis of respiratory syncytial virus clinical isolates in BALB/c mice. J Virol (2011) 1.61
A functional IL-13 receptor is expressed on polarized murine CD4+ Th17 cells and IL-13 signaling attenuates Th17 cytokine production. J Immunol (2009) 1.57
Differential immune responses and pulmonary pathophysiology are induced by two different strains of respiratory syncytial virus. Am J Pathol (2006) 1.55
Activation of EGFR promotes squamous carcinoma SCC10A cell migration and invasion via inducing EMT-like phenotype change and MMP-9-mediated degradation of E-cadherin. J Cell Biochem (2011) 1.52
Influenza vaccines based on virus-like particles. Virus Res (2009) 1.48
Identification of biomarkers for predicting nasopharyngeal carcinoma response to radiotherapy by proteomics. Cancer Res (2010) 1.46
Structural basis of a potent peptide inhibitor designed for Kv1.3 channel, a therapeutic target of autoimmune disease. J Biol Chem (2008) 1.46
Vesicular localization and activity-dependent trafficking of presynaptic choline transporters. J Neurosci (2003) 1.45
Induction of influenza-specific mucosal immunity by an attenuated recombinant Sendai virus. PLoS One (2011) 1.44
Enhanced immunogenicity of stabilized trimeric soluble influenza hemagglutinin. PLoS One (2010) 1.44
Identification of ROS1 rearrangement in gastric adenocarcinoma. Cancer (2013) 1.43
Chronic shear induces caveolae formation and alters ERK and Akt responses in endothelial cells. Am J Physiol Heart Circ Physiol (2003) 1.43
Stabilization of influenza vaccine enhances protection by microneedle delivery in the mouse skin. PLoS One (2009) 1.42
DH166, a beta-carboline derivative, inhibits the kinase activity of PLK1. Cancer Biol Ther (2009) 1.42
Influenza virus inhibits ENaC and lung fluid clearance. Am J Physiol Lung Cell Mol Physiol (2004) 1.40
Influenza virus-like particles containing M2 induce broadly cross protective immunity. PLoS One (2011) 1.40
Protective immunity against H5N1 influenza virus by a single dose vaccination with virus-like particles. Virology (2010) 1.39
Enhanced memory responses to seasonal H1N1 influenza vaccination of the skin with the use of vaccine-coated microneedles. J Infect Dis (2010) 1.36
Human GEN1 and the SLX4-associated nucleases MUS81 and SLX1 are essential for the resolution of replication-induced Holliday junctions. Cell Rep (2013) 1.35
Internet over-users' psychological profiles: a behavior sampling analysis on internet addiction. Cyberpsychol Behav (2003) 1.35
Incorporation of membrane-anchored flagellin into influenza virus-like particles enhances the breadth of immune responses. J Virol (2008) 1.34
Early infection with respiratory syncytial virus impairs regulatory T cell function and increases susceptibility to allergic asthma. Nat Med (2012) 1.33
Preferential target is mitochondria in alpha-mangostin-induced apoptosis in human leukemia HL60 cells. Bioorg Med Chem (2004) 1.33
Expression of Huntington's disease protein results in apoptotic neurons in the brains of cloned transgenic pigs. Hum Mol Genet (2010) 1.33
Transcutaneous immunization with inactivated influenza virus induces protective immune responses. Vaccine (2006) 1.33
Identification of novel nasopharyngeal carcinoma biomarkers by laser capture microdissection and proteomic analysis. Clin Cancer Res (2008) 1.33
Ginseng and Salviae herbs play a role as immune activators and modulate immune responses during influenza virus infection. Vaccine (2006) 1.32
Virus-like particles containing multiple M2 extracellular domains confer improved cross-protection against various subtypes of influenza virus. Mol Ther (2012) 1.31
A stabilized respiratory syncytial virus reverse genetics system amenable to recombination-mediated mutagenesis. Virology (2012) 1.30
Virus-like particle vaccine protects against 2009 H1N1 pandemic influenza virus in mice. PLoS One (2010) 1.28
DNA/MVA vaccine for HIV type 1: effects of codon-optimization and the expression of aggregates or virus-like particles on the immunogenicity of the DNA prime. AIDS Res Hum Retroviruses (2004) 1.27
Two domains that control prefusion stability and transport competence of the measles virus fusion protein. J Virol (2006) 1.26
Structural features of paramyxovirus F protein required for fusion initiation. Biochemistry (2003) 1.26
Incorporation of high levels of chimeric human immunodeficiency virus envelope glycoproteins into virus-like particles. J Virol (2007) 1.25
Fibroblast growth factors: biology, function, and application for tissue regeneration. J Tissue Eng (2010) 1.25
Venezuelan equine encephalitis virus replicon particles encoding respiratory syncytial virus surface glycoproteins induce protective mucosal responses in mice and cotton rats. J Virol (2007) 1.24
A bivalent influenza VLP vaccine confers complete inhibition of virus replication in lungs. Vaccine (2008) 1.24
Ebola virus-like particles produced in insect cells exhibit dendritic cell stimulating activity and induce neutralizing antibodies. Virology (2006) 1.23
Protection against lethal challenge by Ebola virus-like particles produced in insect cells. Virology (2008) 1.22
Intradermal vaccination with influenza virus-like particles by using microneedles induces protection superior to that with intramuscular immunization. J Virol (2010) 1.22
Vaccination inducing broad and improved cross protection against multiple subtypes of influenza A virus. Proc Natl Acad Sci U S A (2010) 1.22
Inhibition of influenza infection by glutathione. Free Radic Biol Med (2003) 1.20
Multiprotein HIV type 1 clade B DNA/MVA vaccine: construction, safety, and immunogenicity in Macaques. AIDS Res Hum Retroviruses (2004) 1.20
Kinetics of immune responses to influenza virus-like particles and dose-dependence of protection with a single vaccination. J Virol (2009) 1.20
Mutations in the putative HR-C region of the measles virus F2 glycoprotein modulate syncytium formation. J Virol (2003) 1.20
Transgenic mice overexpressing reticulon 3 develop neuritic abnormalities. EMBO J (2007) 1.19
TCL1 participates in early embryonic development and is overexpressed in human seminomas. Proc Natl Acad Sci U S A (2002) 1.19
A target site for template-based design of measles virus entry inhibitors. Proc Natl Acad Sci U S A (2004) 1.18
Human tissue mast cells are an inducible reservoir of persistent HIV infection. Blood (2007) 1.17
Design of a small-molecule entry inhibitor with activity against primary measles virus strains. Antimicrob Agents Chemother (2005) 1.17
Improved influenza vaccination in the skin using vaccine coated microneedles. Vaccine (2009) 1.16
Modified HIV envelope proteins with enhanced binding to neutralizing monoclonal antibodies. Virology (2005) 1.16
Human immunodeficiency virus-like particles activate multiple types of immune cells. Virology (2007) 1.16
Palmitoylation of the murine leukemia virus envelope protein is critical for lipid raft association and surface expression. J Virol (2002) 1.16
Salmonella flagellins are potent adjuvants for intranasally administered whole inactivated influenza vaccine. Vaccine (2009) 1.14
Delivery of subunit influenza vaccine to skin with microneedles improves immunogenicity and long-lived protection. Sci Rep (2012) 1.14
Synthetic applications of photoredox catalysis with visible light. Org Biomol Chem (2013) 1.13
Each monomer of the dimeric accessory protein for human mitochondrial DNA polymerase has a distinct role in conferring processivity. J Biol Chem (2009) 1.12